ChemoCentryx, Inc. has provided a corporate update on its pipeline progress and development strategy for its expanding rare renal disease portfolio, which includes the Company’s late stage compounds avacopan (CCX168) as well as CCX140. Avacopan and CCX140 are potent, orally-administered small molecules that selectively inhibit the complement C5a receptor (C5aR), and the chemokine receptor known as CCR2, respectively. Both compounds are in clinical development for the treatment of serious renal diseases. CCX140.